United States set
Menu Shopping cart $0 Search
Distributed product

QuickZyme Human MMP-14 Activity Assay Kit 96-Assays

  • Regulatory status:RUO
  • Type:ELISA
  • Other names:Matrix metalloproteinase-14, MMP14, MMP-X1, Membrane-type matrix metalloproteinase 1, MT-MMP 1, MTMMP1, Membrane-type-1 matrix metalloproteinase, MT1-MMP, MT1MMP
  • Species:Human
Cat. No. Size Price

New QZBMMP14H 96 wells (1 kit) $1246
PubMed Product Details
Technical Data




The QuickZyme human MMP-14 activity assay enables you to specifically measure active human MMP-14. It can be used for the measurement of MMP-14 activity in various biological samples, such as cultured cells and tissue homogenates.

This 96-well plate format assay is based on the QuickZyme technology, using a modified pro-enzyme as a substrate, which upon activation is able to release color from a chromogenic peptide substrate. This amplification step provides a unique assay sensitivity.


Tissue extract, Tissue homogenates, Cells/cell extracts

Sample Requirements

10 - 100 μl


On dry ice. Upon receipt, store the product at the temperature recommended below.


Unopened kit: Store at -20°C, except for the standard, this vial should be stored at -70°C. Do not use kit, or individual kit components past kit expiration date.

Opened kit / reconstituted reagents: Please refer to kit manual.

Calibration Range

0 - 16 ng/ml

Limit of Detection

0.5 ng/ml (2 h incubation)

0.1 ng/ml (5 h incubation)



  • Measures endogenous active MMP-14 / MT1-MMP (naturally occurring) in complex biological samples.

  • Samples: cell extracts, tissue homogenates, tissue extracts.

  • Quantitative.

  • Range: 0.1 to 16 ng/ml

  • Sensitivity: 0.5 ng/ml (2 h incubation with detection reagent); 0.1 ng/ml (5 h incubation with detection reagent).

  • Ease-of-use: Equivalent to ELISA.

Research topic

Bone and cartilage metabolism, Energy metabolism and body weight regulation, Extracellular matrix, Oncology, Pulmonary diseases


Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases responsible for cleaving protein substrates, with the most commonly identified substrates being extracellular matrix (ECM) proteins. MMPs are involved in normal physiological processes, such embryogenesis, organogenesis during development, reproduction tissue resorption, wound healing and tissue remodeling. They also play a role in a number of pathological processes such as inflammation, arthritis, cardiovascular diseases, fibrosis and cancer.

In addition to modulating the components of the extracellular connective tissue, matrix metalloproteinases also regulate cell proliferation, differentiation, migration, apoptosis, and vessel regeneration indirectly by cleaving and activating vital molecules that control cell function, or directly by binding to cell surface molecules that trigger activation of intracellular pathways.

Regulation of MMPs is carried out at various levels. Expression of latent MMPs is regulated at the level of transcription, whereas the proteolytic activity is controlled by specific activation of proMMPs, and by MMP-specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), or general circulatory inhibitors, such as α2macroglobulin. The MMPs can be grouped according to their domain structure into collagenases, gelatinases, stromelysins, membrane type MMPs and matrilysins.

MMP- 14 (EC, also known as MT- MMP or MT1-MMP, is a membrane type MMP and contains a transmembrane domain. MMP-14 has a role in the activation of the proforms of MMP-2 and MMP-13. MMP-14 is believed to be involved in bone and tooth development, tumor cell invasion and cell migration and also in shedding of a variety of cell surface proteins. Furthermore, MMP-14 is able to directly degrade certain matrix proteins such as laminin, fibronectin, vitronectin and interstitial collagens. Recent work points to an involvement of MMP-14 in plaque vulnerability. Human MMP-14 consists of 562 amino acid residues including a propeptide of 91 residues and is most likely intracellularly activated by furin-like enzymes and transported to the membrane as an active enzyme. MMP-14 is thought to be released from the cell membrane by proteolytic cleavage. The activity is dependent on Zn2+ and Ca2+.

MMP-14 has have been shown to correlate with a variety of physiological functions and tumor-related behaviors such as migration, invasion, metastasis, basement membrane remodeling, and angiogenesis. MMP-14 is overexpressed in most human cancer, and the published studies have demonstrated that overexpression of MMP-14 in various cancers is associated with poor prognosis. It was found that microRNA miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of MMP-14, suggesting that miR-181a-5p could serve as a potential prognostic biomarker and molecular target for the prevention of cancer metastasis. Further, it has been demonstrated that interleukin-6 (IL-6) increases MMP-14 levels via down-regulation of p53 to drive cancer progression.

MMP-14 is the predominant pericellular collagenase in adipose tissue. Its mRNA levels are upregulated during obesity, along with many other MMPs. Loss-of-function of MMP14 leads to impaired adipose tissue formation, eventually leading to severe lipodystrophy in mice. A genetic variant in the human MMP14 gene has been found to be linked to obesity and diabetes. Together, these findings demonstrate a key role of MMP14 in physiological/pathological remodeling of adipose tissue.

MMP-14 has a pivotal role in adult collagen homeostasis, and inhibition of its expression and activity may contribute to pathogenesis of fibrosis. The pathogenic role MMP-14 has been investigated with respect to fibrotic disease of the skin, liver, lungs, and others.

Summary References (19)

References to MMP-14

  • Cathcart JM, Banach A, Liu A, Chen J, Goligorsky M, Cao J. Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression. Oncotarget. 2016 Sep 20;7(38):61107-61120. doi: 10.18632/oncotarget.11243. PMID: 27531896; PMCID: PMC5308639. See more on PubMed
  • Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40(6-7):1362-78. doi: 10.1016/j.biocel.2007.12.006. Epub 2007 Dec 24. PMID: 18258475. See more on PubMed
  • DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol. 2014 Dec;77:64-72. doi: 10.1016/j.yjmcc.2014.09.016. Epub 2014 Sep 28. PMID: 25261607; PMCID: PMC4312173. See more on PubMed
  • Duan F, Peng Z, Yin J, Yang Z, Shang J. Expression of MMP-14 and prognosis in digestive system carcinoma: a meta-analysis and databases validation. J Cancer. 2020 Jan 1;11(5):1141-1150. doi: 10.7150/jca.36469. PMID: 31956360; PMCID: PMC6959085. See more on PubMed
  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9. PMID: 25220842. See more on PubMed
  • Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, Tartare-Deckert S. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 2003 Apr 4;278(14):11888-96. doi: 10.1074/jbc.M209196200. Epub 2003 Jan 15. PMID: 12529376. See more on PubMed
  • Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013;2013:928315. doi: 10.1155/2013/928315. Epub 2013 Jun 12. PMID: 23840100; PMCID: PMC3694547. See more on PubMed
  • Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell. 2006 May 5;125(3):577-91. doi: 10.1016/j.cell.2006.02.050. PMID: 16678100. See more on PubMed
  • Chun TH, Inoue M, Morisaki H, Yamanaka I, Miyamoto Y, Okamura T, Sato- Kusubata K, Weiss SJ. Genetic link between obesity and MMP14-dependent adipogenic collagen turnover. Diabetes. 2010 Oct;59(10):2484-94. doi: 10.2337/db10-0073. Epub 2010 Jul 26. PMID: 20660624; PMCID: PMC3279534. See more on PubMed
  • Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol. 2006 Jan;206(1):1-8. doi: 10.1002/jcp.20431. PMID: 15920734. See more on PubMed
  • Li X, Zhao Y, Chen C, Yang L, Lee HH, Wang Z, Zhang N, Kolonin MG, An Z, Ge X, Scherer PE, Sun K. Critical Role of Matrix Metalloproteinase 14 in Adipose Tissue Remodeling during Obesity. Mol Cell Biol. 2020 Mar 30;40(8):e00564-19. doi: 10.1128/MCB.00564-19. PMID: 31988105; PMCID: PMC7108820. See more on PubMed
  • Li Y, Kuscu C, Banach A, Zhang Q, Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, Denoya PI, Zhu X, Chen L, Cao J. miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14. Cancer Res. 2015 Jul 1;75(13):2674-85. doi: 10.1158/0008-5472.CAN-14-2875. Epub 2015 May 14. PMID: 25977338; PMCID: PMC4489986. See more on PubMed
  • Lin D, Chun TH, Kang L. Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem Pharmacol. 2016 Nov 1;119:8-16. doi: 10.1016/j.bcp.2016.05.005. Epub 2016 May 12. PMID: 27179976; PMCID: PMC5061598. See more on PubMed
  • Ling B, Watt K, Banerjee S, Newsted D, Truesdell P, Adams J, Sidhu SS, Craig AWB. A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget. 2017 May 9;8(35):58372-58385. doi: 10.18632/oncotarget.17702. PMID: 28938563; PMCID: PMC5601659. See more on PubMed
  • Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016 Mar 4;17:23. doi: 10.1186/s12931-016-0343-6. PMID: 26944412; PMCID: PMC4779202. See more on PubMed
  • Remacle AG, Cieplak P, Nam DH, Shiryaev SA, Ge X, Strongin AY. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Oncotarget. 2017 Jan 10;8(2):2781-2799. doi: 10.18632/oncotarget.13157. PMID: 27835863; PMCID: PMC5356841. See more on PubMed
  • Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003 May 8;194(1):1-11. doi: 10.1016/s0304-3835(02)00699-7. PMID: 12706853. See more on PubMed
  • Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJ, Iredale JP, Benyon RC. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int. 2004 Oct;24(5):492-501. doi: 10.1111/j.1478-3231.2004.0946.x. PMID: 15482348. See more on PubMed
  • Zigrino P, Brinckmann J, Niehoff A, Lu Y, Giebeler N, Eckes B, Kadler KE, Mauch C. Fibroblast-Derived MMP-14 Regulates Collagen Homeostasis in Adult Skin. J Invest Dermatol. 2016 Aug;136(8):1575-1583. doi: 10.1016/j.jid.2016.03.036. Epub 2016 Apr 9. PMID: 27066886; PMCID: PMC4946792. See more on PubMed
Related Products Docs